Survival in small cell lung carcinoma is independent of bcl-2 expression

Anirban Maitra, Robin H. Amirkhan, M. Hossein Saboorian, William H. Frawley, Raheela Ashfaq

Research output: Contribution to journalArticle

Abstract

Bcl-2 overexpression is a common event in small cell carcinomas (SCLC). The bcl-2 oncoprotein has a unique oncogenic role by inhibiting programmed cell death (apoptosis), resulting in tumorigenesis and chemoresistance. Forty-two cases of SCLC were stained immunohistochemically with bcl-2 monoclonal antibody (Biogenex, San Ramon, CA) after using an antigen retrieval step with citrate buffer, bcl-2 positivity was determined as detection of the oncoprotein in greater than 10% of noncrushed neoplastic cells. Twenty-five of 42 (60%) patients had extensive disease at presentation, 10 of 42 (24%) had limited disease, and 7 of 42 (16%) had disease localized to the lung. Twenty-four of 42 (57%) tumors were bcl-2 positive, and 18 of 42 (43%) tumors were bcl-2 negative. Follow-up in patients ranged from 7 days to 96 months (mean follow-up, 20 months). The median survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bcl-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC.

Original languageEnglish (US)
Pages (from-to)712-717
Number of pages6
JournalHuman Pathology
Volume30
Issue number6
DOIs
StatePublished - Jun 1999
Externally publishedYes

Fingerprint

Small Cell Carcinoma
Small Cell Lung Carcinoma
Survival
Oncogene Proteins
Neoplasms
Proportional Hazards Models
Citric Acid
Buffers
Carcinogenesis
Cell Death
Monoclonal Antibodies
Apoptosis
Antigens
Lung

Keywords

  • Bcl-2
  • Lung cancer
  • Small cell
  • Survival

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Maitra, A., Amirkhan, R. H., Saboorian, M. H., Frawley, W. H., & Ashfaq, R. (1999). Survival in small cell lung carcinoma is independent of bcl-2 expression. Human Pathology, 30(6), 712-717. https://doi.org/10.1016/S0046-8177(99)90099-0

Survival in small cell lung carcinoma is independent of bcl-2 expression. / Maitra, Anirban; Amirkhan, Robin H.; Saboorian, M. Hossein; Frawley, William H.; Ashfaq, Raheela.

In: Human Pathology, Vol. 30, No. 6, 06.1999, p. 712-717.

Research output: Contribution to journalArticle

Maitra, A, Amirkhan, RH, Saboorian, MH, Frawley, WH & Ashfaq, R 1999, 'Survival in small cell lung carcinoma is independent of bcl-2 expression', Human Pathology, vol. 30, no. 6, pp. 712-717. https://doi.org/10.1016/S0046-8177(99)90099-0
Maitra, Anirban ; Amirkhan, Robin H. ; Saboorian, M. Hossein ; Frawley, William H. ; Ashfaq, Raheela. / Survival in small cell lung carcinoma is independent of bcl-2 expression. In: Human Pathology. 1999 ; Vol. 30, No. 6. pp. 712-717.
@article{784b47448dbb4943899bfbe668e7fdf3,
title = "Survival in small cell lung carcinoma is independent of bcl-2 expression",
abstract = "Bcl-2 overexpression is a common event in small cell carcinomas (SCLC). The bcl-2 oncoprotein has a unique oncogenic role by inhibiting programmed cell death (apoptosis), resulting in tumorigenesis and chemoresistance. Forty-two cases of SCLC were stained immunohistochemically with bcl-2 monoclonal antibody (Biogenex, San Ramon, CA) after using an antigen retrieval step with citrate buffer, bcl-2 positivity was determined as detection of the oncoprotein in greater than 10{\%} of noncrushed neoplastic cells. Twenty-five of 42 (60{\%}) patients had extensive disease at presentation, 10 of 42 (24{\%}) had limited disease, and 7 of 42 (16{\%}) had disease localized to the lung. Twenty-four of 42 (57{\%}) tumors were bcl-2 positive, and 18 of 42 (43{\%}) tumors were bcl-2 negative. Follow-up in patients ranged from 7 days to 96 months (mean follow-up, 20 months). The median survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bcl-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC.",
keywords = "Bcl-2, Lung cancer, Small cell, Survival",
author = "Anirban Maitra and Amirkhan, {Robin H.} and Saboorian, {M. Hossein} and Frawley, {William H.} and Raheela Ashfaq",
year = "1999",
month = "6",
doi = "10.1016/S0046-8177(99)90099-0",
language = "English (US)",
volume = "30",
pages = "712--717",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Survival in small cell lung carcinoma is independent of bcl-2 expression

AU - Maitra, Anirban

AU - Amirkhan, Robin H.

AU - Saboorian, M. Hossein

AU - Frawley, William H.

AU - Ashfaq, Raheela

PY - 1999/6

Y1 - 1999/6

N2 - Bcl-2 overexpression is a common event in small cell carcinomas (SCLC). The bcl-2 oncoprotein has a unique oncogenic role by inhibiting programmed cell death (apoptosis), resulting in tumorigenesis and chemoresistance. Forty-two cases of SCLC were stained immunohistochemically with bcl-2 monoclonal antibody (Biogenex, San Ramon, CA) after using an antigen retrieval step with citrate buffer, bcl-2 positivity was determined as detection of the oncoprotein in greater than 10% of noncrushed neoplastic cells. Twenty-five of 42 (60%) patients had extensive disease at presentation, 10 of 42 (24%) had limited disease, and 7 of 42 (16%) had disease localized to the lung. Twenty-four of 42 (57%) tumors were bcl-2 positive, and 18 of 42 (43%) tumors were bcl-2 negative. Follow-up in patients ranged from 7 days to 96 months (mean follow-up, 20 months). The median survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bcl-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC.

AB - Bcl-2 overexpression is a common event in small cell carcinomas (SCLC). The bcl-2 oncoprotein has a unique oncogenic role by inhibiting programmed cell death (apoptosis), resulting in tumorigenesis and chemoresistance. Forty-two cases of SCLC were stained immunohistochemically with bcl-2 monoclonal antibody (Biogenex, San Ramon, CA) after using an antigen retrieval step with citrate buffer, bcl-2 positivity was determined as detection of the oncoprotein in greater than 10% of noncrushed neoplastic cells. Twenty-five of 42 (60%) patients had extensive disease at presentation, 10 of 42 (24%) had limited disease, and 7 of 42 (16%) had disease localized to the lung. Twenty-four of 42 (57%) tumors were bcl-2 positive, and 18 of 42 (43%) tumors were bcl-2 negative. Follow-up in patients ranged from 7 days to 96 months (mean follow-up, 20 months). The median survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bcl-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC.

KW - Bcl-2

KW - Lung cancer

KW - Small cell

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0033025610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033025610&partnerID=8YFLogxK

U2 - 10.1016/S0046-8177(99)90099-0

DO - 10.1016/S0046-8177(99)90099-0

M3 - Article

C2 - 10374782

AN - SCOPUS:0033025610

VL - 30

SP - 712

EP - 717

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 6

ER -